Are you ready to join the Ozempic lawsuit? Recent FDA findings show Ozempic may significantly increase the risk of serious abdominal pain and health issues. If harmed by Ozempic, you could be eligible for compensation

Ozempic, a common drug for type-2 diabetes and weight loss, is under scrutiny. Manufacturer Novo Nordisk allegedly didn’t properly warn of abdominal complications such as gallbladder disease and intestinal blockage.

Our attorneys at Rueb Stoller Daniel are ready to help you seek justice and financial relief.

Contact us today at 1-866-CALL-RSD to see if you qualify for compensation.

Ozempic Lawsuit Updates

April 2024:  Novo Nordisk, the maker of Ozempic, is actively litigating against pharmacies that distribute unapproved compounded versions of semaglutide, which includes drugs like Ozempic, Wegovy, and Rybelsus. The FDA has expressed concerns and advised the National Association of Boards of Pharmacy against compounding these medications, citing violations of federal law.

On January 10, 2024, the FDA highlighted the growing issue and risks associated with counterfeit versions of Ozempic, particularly compounded forms. Novo Nordisk has already reached settlements with several pharmacies that were found to be selling these non-authentic versions. Additionally, there is an ongoing federal lawsuit challenging the safety of Ozempic itself, asserting that the drug poses significant risks that have not been adequately disclosed by the manufacturer.

March 2024: The class action lawsuit’s momentum is set to increase with the first status conference scheduled for March 14, 2024. This meeting will provide an early insight into how U.S. District Judge Gene E.K. Pratter will navigate through the complexities of this litigation.

February 2024: Recent studies have highlighted the benefits of using well-known GLP-1 receptor agonist medications like Ozempic, Wegovy, and Mounjaro for patients, particularly in the management of diabetes and weight loss. Despite their efficacy, there’s an increased risk of gastrointestinal issues, such as nausea, vomiting, and other digestive problems, especially at higher doses. This suggests a need for careful dosing to mitigate adverse effects.

Mounjaro has been singled out as the most effective among these GLP-1RAs in improving glycemic control, demonstrating significant reductions in hemoglobin A1c and fasting plasma glucose levels.

Legal actions are now unfolding, with Ozempic lawsuits being initiated in New Jersey state court and within a newly formed multidistrict litigation (MDL). In a notable case, Tinsley v. Novo Nordisk, the plaintiff claims that her use of Ozempic led to a gallbladder injury, requiring surgical removal on February 2, 2022, under the New Jersey Products Liability Act.

These developments underscore a common concern: the need for more comprehensive knowledge about these medications. A recent study, for instance, revealed a “significant association” between the use of GLP-1 receptor agonists and psychiatric side effects, adding another layer to the ongoing debate about these drugs’ safety profile.

January 2024: The FDA is currently assessing reported cases of hair loss, suicidal thoughts, and aspiration during sedation and anesthesia in individuals using Ozempic and other similar medications for diabetes and weight loss. This evaluation is in response to numerous reports of these potential adverse effects logged in the FDA Adverse Event Reporting System database.

January 2024: There are some recent developments regarding the potential consolidation of Mounjaro and Ozempic lawsuits into a class action and the ability for the an Ozempic case to move forward:

Novo Nordisk, the manufacturer of Ozempic, supports the consolidation of the lawsuits, citing shared factual, scientific, and legal issues among the 41 suits filed in 17 federal courts. They have suggested either the Western District of Louisiana or the Southern District of California for the consolidated proceeding.

On the other hand, Eli Lilly, the manufacturer of Mounjaro, opposes being included in the combined litigation. They argue that most cases focus on Novo Nordisk’s Ozempic, especially its use for weight loss, a claim not associated with Lilly’s products, Mounjaro and Trulicity, which are approved for type 2 diabetes treatment, not weight loss.

The differences in the positions of the two defendants may complicate the path to a consolidated class action, but the decision on this issue will ultimately be made by the legal authorities involved.

December 2023: The federal judge in Louisiana has made a significant decision in the lawsuit against Novo Nordisk Inc. regarding the diabetes drug Ozempic. While the judge dismissed claims of breach of express warranty, other claims related to inadequate warnings, particularly concerning the side effect of gastroparesis, have been allowed to proceed. The judge also recognized the importance of the complaint’s claims regarding inadequate warnings for physicians under Louisiana’s learned intermediary doctrine.

This ruling underscores the importance of the warnings aspect in Ozempic lawsuits and the need for drug companies to provide clear and sufficient information to both patients and healthcare professionals about potential side effects and risks associated with their medications. It’s worth noting that similar claims against Eli Lilly & Co.’s drug Mounjaro are still pending, and further decisions will be awaited in that regard.

December 2023: The European Medicines Agency (EMA) is currently conducting an investigation to determine whether there is a potential link between the use of certain diabetes and weight loss drugs, including Ozempic, Wegovy, and other GLP-1 receptor agonists, and an increased risk of suicidal thoughts and self-harm. This investigation highlights concerns regarding the safety and potential side effects of these medications.

While your Ozempic lawyers are focused on lawsuits related to gallbladder disease and gastrointestinal disorders, such as gastroparesis or cyclic vomiting syndrome, the question of a potential correlation between suicide and these drugs raises broader concerns about their safety and the need for further research and scrutiny. It’s essential to investigate and monitor the safety of medications, especially when there are reports of adverse effects or potential risks associated with their use. Drug companies have a responsibility to prioritize patient safety and provide accurate information about the potential risks and benefits of their products.

December 2023: The motion filed with the U.S. Judicial Panel on Multidistrict Litigation (JPML) seeks to centralize all federal gastroparesis lawsuits related to Ozempic, Wegovy, Mounjaro, and similar GLP-1 receptor agonist drugs under the supervision of U.S. District Judge James D. Cain, Jr. in the Western District of Louisiana. While this consolidation is similar to the process of a class action in that it centralizes pretrial proceedings for efficiency, it’s important to note that an MDL (Multidistrict Litigation) and a class action are legally distinct processes.

In an MDL, individual lawsuits with common issues are consolidated for pretrial proceedings, such as evidence gathering and discovery, but each case remains separate and may return to its original court for trial. On the other hand, in a class action, a group of plaintiffs is treated as a single entity, and the outcome of the case applies to the entire class.

Currently, there are 18 cases pending across various U.S. District Courts related to gastroparesis and these drugs, but it’s possible that more cases will be added, given the widespread use of these medications. The creation of an MDL is likely in this situation due to the significant number of cases and common issues involved.

November 2023: Novo Nordisk is facing a class action lawsuit in Canada, similar to lawsuits in the United States, over allegations that the pharmaceutical company failed to provide adequate warnings about the risk of gastroparesis associated with its drug Ozempic. This condition has also been the subject of lawsuits in the United States, and it appears that individuals in Canada are pursuing legal action on similar grounds. The lawsuit highlights concerns about the information provided to patients regarding the potential side effects of Ozempic.

October 2023: The release of a new study in the Journal of the American Medical Association regarding the potential risks associated with weight loss medications like Ozempic and Wegovy is likely to lead to an increase in Ozempic lawsuit filings in 2023. This study highlights a potential heightened risk of serious gastrointestinal issues for individuals using these medications, which contain semaglutide. It also adds to the existing body of evidence linking weight loss drugs known as GLP-1 agonists to stomach-related risks. As a result, it is expected that more Ozempic lawyers will advertise their services in response to this study, and individuals who believe they have been harmed by these medications may seek legal action.

September 2023: The FDA has revised the label for the diabetes medication Ozempic to include possible intestinal blockage in side effects. Ozempic, along with its related weight loss drug Wegovy, has grown in popularity. The labels for Wegovy and another diabetes medicine, Mounjaro, have been changed to note this potential issue. Now, Ozempic’s label reflects the same.

August 2023: Jaclyn Bjorklund emerged as one of the initial individuals to lodge a gastroparesis lawsuit against Ozempic and Mounjaro. On August 3, legal notices were dispatched to both Novo Nordisk and Eli Lilly.

July 2023: ASHP, recognized as the United States’ foremost association of pharmacy specialists, notified that Novo Nordisk was experiencing a shortage of both Ozempic and Wegovy—a different semaglutide—attributed to heightened demand.

August 2022: A decision was made by the judiciary to consolidate seven lawsuits against Novo Nordisk into a multidistrict litigation (MDL) in Delaware. These suits were against generic pharmaceutical manufacturers for alleged patent violations. These defendants had sought approvals from the FDA to produce generic variants of Ozempic. Furthermore, in the same month, following the publication of a scientific letter in JAMA Internal Medicine that connected Ozempic with an escalated risk of gallbladder ailments and gallstones, legal experts started to entertain Ozempic gallbladder-related lawsuits.

About Ozempic - Ozempic lawsuits from gallbladder disease | file an Ozempic lawsuit with RSD today

What is the Ozempic Lawsuit About?

The Ozempic lawsuit is a legal recourse available to individuals who have suffered harm or injury as a result of taking the medication. However, it’s important to understand that not all adverse effects from taking Ozempic will qualify for a lawsuit.

To successfully file an Ozempic gallbladder lawsuit, you need to meet the following requirements:

  • You used Ozempic before March 2022
  • You were later diagnosed with related gallbladder issues
  • You received medical treatment for the complications

Since Ozempic is not officially approved for weight loss, cases involving injuries resulting from such uses may have a lesser chance of success. However, the presence of certain circumstances can provide legal grounds for a lawsuit. These include:

  • Insufficient warnings were provided by the manufacturer regarding the risks associated with Ozempic usage.
  • The defective manufacturing or labeling of Ozempic directly led to your injury.
  • The manufacturer made explicit or implicit guarantees about the safety or efficacy of Ozempic that it failed to fulfill.

To assess the viability of your case, it is essential to consult with a skilled mass tort attorney who can evaluate the intricacies of your situation.

Contact us today at 1-866-CALL-RSD to start the claims process.

What Can You Receive From Ozempic Lawsuits?

By filing an Ozempic lawsuit, you may be entitled to various forms of compensation. These can include medical expenses, pain and suffering, lost wages, emotional distress, and other damages resulting from the injuries caused by Ozempic. Each case is unique, and our experienced attorneys will assess the specifics of your situation to help determine the full extent of your potential compensation.

How Can I File an Ozempic Lawsuit?

Filing an Ozempic lawsuit may seem like a daunting process, but Rueb Stoller Daniel is here to guide you every step of the way. Our dedicated team of legal professionals has extensive experience handling pharmaceutical injury cases and will ensure that your rights are protected.

To get started, simply reach out to us for a free consultation, and we will evaluate your case, answer your questions, and provide you with the support you need.

We will diligently gather compelling evidence, including your medical records and testimony, to construct a robust and persuasive case.

We will also ensure that your Ozempic lawsuit within the applicable statutes of limitations or state deadlines.

Throughout the legal process, we will engage in skillful negotiations with the defendant(s) to secure a favorable Ozempic settlement that adequately compensates you for the damages you have suffered.

In the event that a settlement cannot be reached, rest assured that our dedicated attorneys will be prepared to present your case in a court trial.

What is Ozempic?

Man injecting oempic in his stomach, he may can file for an Ozempic lawsuit

Ozempic, also known by its generic name semaglutide, is an injectable prescription medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes.

It belongs to a class of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists, which work by stimulating insulin production and lowering blood sugar levels.

Despite being officially approved solely for the treatment of diabetes, Ozempic has gained significant attention and popularity due to its ability to treat obesity and aid in weight loss.

How It Works

Ozempic works by stimulating the release of insulin, a hormone responsible for regulating blood sugar levels. By activating GLP-1 receptors, it assists the body in managing glucose and curbing appetite. However, despite its intended benefits, Ozempic has been associated with a range of potential side effects.

Side Effects of Ozempic (Stomach Paralysis, Acute Gallbladder Disease, and more)

While Ozempic has shown efficacy in managing blood sugar levels, it is important to be aware of potential side effects. Commonly reported side effects include nausea, vomiting, diarrhea, and constipation.

However, more severe complications have recently been observed, particularly regarding the gallbladder and pancreas. Symptoms have included stomach paralysis, gallbladder disease, and even pancreatic cancer.

What Happens After You Stop Using It?

Discontinuing the use of Ozempic does not guarantee that its side effects will dissipate entirely. In fact, many individuals who have stopped using Ozempic have reported persistent gallbladder issues and other related injuries.

This concerning trend has raised significant questions about the safety and long-term effects of this medication.

Ozempic Linked to Gallbladder Problems

Ozempic lawsuits are being filed due to gallbladder disease. The popular weight loss solution from drug manufacturer Novo Nordisk is developing severe gastrointestinal issues in users.

Recent research published in JAMA Internal Medicine revealed a concerning connection between Ozempic and gallbladder problems. FDA data showed that Ozempic users for type 2 diabetes treatment had higher rates of gallbladder conditions, including acute gallbladder disease(cholecystitis) and gallstones (cholelithiasis).

Gallstones, the prevalent form of gallbladder disease, are solid deposits resembling pebbles that develop within the gallbladder.

Acute gallbladder disease, on the other hand, is a serious condition that is characterized by the sudden inflammation of the gallbladder, often caused by the obstruction of the gallbladder’s outlet tube due to the presence of gallstones. It requires hospital treatment to prevent further complications, often necessitating surgical removal of the gallbladder.

The researchers observed that the risk of gallbladder problems from Ozempic was higher when the drug was administered at higher doses, for longer durations, or for the purpose of weight loss.

The findings align with the conclusions drawn from two prior meta-analysis studies on the association between drugs similar to Ozempic and gallbladder problems.

Ozempic linked to Pancreatic Cancer

Recent studies show worries about using Ozempic. There are fears that it might be linked to pancreatitis and even pancreatic cancer.

If you or someone you know had health problems because of Ozempic, it’s important to know what’s happening and think about taking legal action if needed.

If you think Ozempic hurt your health, take action. Talk to experienced lawyers. With growing concerns about the safety of Ozempic, patients need to stay updated and do what’s best for them.

Ozempic and Intestinal Injuries

Ozempic class action lawsuit | Ozempic gallbladder lawsuits are becoming more popular

Recent findings show there may be dangers with injectable medications that have semaglutide (like Ozempic) because they can cause problems in the intestines. If someone ends up in the hospital or dies because of these issues, they may be eligible for financial compensation for medical bills and pain and suffering.

These drugs can make the stomach digest food more slowly. Sometimes, this can cause serious stomach pain, leading to a condition called “gastroparesis” or stomach paralysis.

On August 2, a woman named Jaclyn Bjorklund, who is 44 and lives in Louisiana, started a lawsuit. She lost 150 pounds with her doctor’s help using these drugs but says they caused her to have stomach paralysis.

Her lawyers stress that these problems could affect her for the rest of her life. She’s mainly suing the big drug company Novo Nordisk (who makes Ozempic) because they didn’t warn people about the chance of major stomach issues.

Understanding Gastroparesis

The phenomenon of stomach paralysis can be triggered by a many of reasons, yet it is a recognized adverse effect of GLP-1 drugs, including but not limited to Ozempic.

Extended delays in food passage from the stomach, a manifestation of gastroparesis, can result in the formation of solid aggregates also called bezoars, as elucidated by the National Institutes of Health (NIH). The ensuing complications can encompass intestinal obstructions and severe vomiting, among other challenges.

The broader spectrum of symptoms associated with gastrointestinal paralysis also covers more frequent issues like nausea and excessive vomiting too.

Dr. Shilpa Mehra Dang, an esteemed gastroenterologist stationed at the Medical Offices of Manhattan, underscores the paramount importance of vigilance, urging both medical professionals and patients to be acutely cognizant of these potential ramifications.

Ozempic lawsuits from gallbladder disease | File an Ozempic lawsuit with RSD today

Get In Touch With An Experienced Mass Tort Lawyer!

If you or a loved one have experienced harm or injury from the use of Ozempic, you don’t have to face the consequences alone. At Rueb Stoller Daniel Law Firm, we are here to stand by your side and fight for your rights. Our dedicated team of attorneys has the knowledge, experience, and determination to pursue justice on your behalf.

Contact Rueb Stoller Daniel Law Firm at 1-866-CALL-RSD  to schedule your free consultation and initiate your Ozempic lawsuit.